Related references
Note: Only part of the references are listed.Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a vaccinal effect of rituximab
Shannon P. Hilchey et al.
BLOOD (2009)
CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas
Edmund A. Rossi et al.
BLOOD (2009)
Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma
David J. Betting et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas
Tove Olafsen et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Inhibitors of MyD88-Dependent Proinflammatory Cytokine Production Identified Utilizing a Novel RNA Interference Screening Approach
John S. Cho et al.
PLOS ONE (2009)
Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis
Michele De Palma et al.
CANCER CELL (2008)
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma:: Results of a phase II study
Guillaume Cartron et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
Eva Kimby et al.
LEUKEMIA & LYMPHOMA (2008)
Interferons at age 50: past, current and future impact on biomedicine
Ernest C. Borden et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Targeting IFN-α to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities
Tzu-Hsuan Huang et al.
JOURNAL OF IMMUNOLOGY (2007)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
Ali R. Jazirehi et al.
CANCER RESEARCH (2007)
Alpha-interferon for relapsed non-Hodgkin's lymphoma
A. E. Armitage et al.
BONE MARROW TRANSPLANTATION (2006)
A time- and cost-efficient system for high-level protein production in mammalian cells
A. Radu Aricescu et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma
E. Brin et al.
CANCER GENE THERAPY (2006)
Intra-lesional low-dose interferon α2a therapy for primary cutaneous marginal zone B-cell lymphoma
Antonio Cozzio et al.
LEUKEMIA & LYMPHOMA (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunotherapy for non-Hodgkin's lymphoma: Monoclonal antibodies and vaccines
DG Maloney
JOURNAL OF CLINICAL ONCOLOGY (2005)
Milstein Award Lecture: Interferons and cancer: Where from here?
EC Borden
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Meta-analysis to evaluate the role of interferon in follicular lymphoma
AZS Rohatiner et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response
WL Gluck et al.
CLINICAL CANCER RESEARCH (2004)
A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma
P Neeson et al.
CYTOMETRY PART A (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Systemic remission of non-Hodgkin's lymphoma after intralesional interferon alpha-2b to bilateral conjunctival lymphomas
JJ Ross et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Adenovirus-mediated gene transfer of interferon α improves dimethylnitrosamine-induced liver cirrhosis in rat model
K Suzuki et al.
GENE THERAPY (2003)
Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis
M Chawla-Sarkar et al.
APOPTOSIS (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
SM Ansell et al.
BLOOD (2002)
Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
E Jonasch et al.
ONCOLOGIST (2001)
Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-α cleavage during IFN-α-induced apoptosis in Daudi B lymphoma cells
N Yanase et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2000)
Effect of interferon-α on CD20 antigen expression of B-cell chronic lymphocytic leukemia
S Sivaraman et al.
CYTOKINES CELLULAR & MOLECULAR THERAPY (2000)
Activity of interferon-α in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
JO Armitage et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
